mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022

For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we esti-mated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using sur-veillance data. In the most vulnerable age group com-prising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95???96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79???84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.